TY-302
Asset
Antineoplastic agent
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Not known
- 2
- Indications
- 278
- Trials
- 1
- Developer
Indications
2Breast cancer
Phase 1, Unknown, NCT04433494, clinicaltrials.gov, 7 Oct 2026
Solid tumor
Phase 1, Unknown, NCT04433494, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials278
- Evidence for its targets1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.